8 results match your criteria: "and Tokai University[Affiliation]"
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med
October 2024
From the Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom (W.G.H., N.S., N.A., C.W., J.R.E., D.P., P.J., D.Z., R. Dayanandan, R.A., K.J.M., S.Y.A.N., E.S., W.S., K.W., M.H., M.J.L., C.B., R.H.); the University Clinic of Würzburg, Würzburg (C.W., S.B.), Boehringer Ingelheim International (S.J.H., D.S., M.B.), Elderbrook Solutions (D.M.), and the Fifth Department of Medicine, University Medical Center Mannheim (S.J.H.) and the First Department of Medicine, Faculty of Medicine Mannheim (M.B.), University of Heidelberg, Mannheim, and the Department of Nephrology, Hospital Rechts der Isar, Technical University of Munich, Munich (D.S.) - all in Germany; Duke Clinical Research Institute, Durham, NC (J.B.G.); the University of Utah, Salt Lake City (A.K.C.); the National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing (Z.-H.L.), and Fuwai Hospital, Chinese Academy of Medical Sciences, National Center for Cardiovascular Diseases, Beijing (J.L.) - both in China; Hospital Sultanah Aminah, Johor Bahru, Malaysia (L.S.H., W.L.); the University of Tokyo School of Medicine/Toranomon Hospital (T.K.) and the University of Tokyo School of Medicine (M.N.), Tokyo, and Tokai University School of Medicine, Isehara (S.G.) - all in Japan; the University of British Columbia, Vancouver (A.L.), and the University of Toronto, Toronto (D.Z.I.C.) - both in Canada; Università degli Studi and IRCCS Ospedale Policlinico San Martino di Genova, Genoa (R.P.), and Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Florence (A.P.M.) - both in Italy; the University of Pennsylvania Perelman School of Medicine, Philadelphia (R. Deo); Providence Health Care and University of Washington, Seattle (K.R.T.); and Hospital Universitario Son Espases, Health Research Institute of the Balearic Islands, Universitat Illes Balears, Palma de Mallorca, Spain (X.R.).
Article Synopsis
- The EMPA-KIDNEY trial examined the effects of empagliflozin, an SGLT2 inhibitor, on patients with chronic kidney disease at risk for progression, assessing outcomes during and after the trial.
- A total of 6609 patients were randomized, with 4891 participating in a follow-up period after the trial where they were observed for an additional 2 years, without trial medication but allowed to use other SGLT2 inhibitors.
- Results showed that fewer primary outcome events (like kidney disease progression or cardiovascular death) occurred in the empagliflozin group (26.2%) compared to the placebo group (30.3%), suggesting lasting benefits of the drug even after the trial ended. *
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med
July 2022
From the Memorial Sloan Kettering Cancer Center, New York (S.M.); Institut du Cancer de Montpellier, Université Montpellier, INSERM Unité 1194, Montpellier (W.J.), and Institut Curie, Université Paris Cité, Paris (J.-Y.P.) - both in France; Kanagawa Cancer Center, Yokohama (T.Y.), Kyushu Cancer Center, National Hospital Organization, Fukuoka (E.T.), Showa University Hospital, Tokyo (J.T.), and Tokai University School of Medicine, Isehara-shi (N.N.) - all in Japan; Yonsei Cancer Center, Yonsei University Health System (J. Sohn), Samsung Medical Center (Y.H.P.), Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University (S.-A.I.), and Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Seoul, Kyungpook National University Chilgok Hospital, Daegu (Y.S.C.), and the National Cancer Center, Goyang-si (K.S.L.) - all in South Korea; the Department of Medical Oncology, Hospital Clínic de Barcelona (M.V., A.P.), Translational Genomics and Targeted Therapies in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (A.P.), the Department of Medicine, University of Barcelona (A.P.), the Breast Cancer Unit, Institute of Oncology (IOB)-Quirón Salud (A.P.), Institut Catala d'Oncologia l'Hospitalet-Hospital Duran i Reynals (M.G.-G.), and Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (C.S.) - all in Barcelona; the University of Texas M.D. Anderson Cancer Center, Houston (N.T.U.); Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (B.X.), Zhejiang Cancer Hospital, Hangzhou (X.W.), the First Hospital of Jilin University, Changchun (W.L.), Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou (Q.L.), West China Hospital, Sichuan University, Chengdu (T.L.), and Liaoning Cancer Hospital and Institute, Shenyang (T.S.) - all in China; the Cleveland Clinic Foundation, Cleveland (H.C.F.M.); the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (H.S.R.); Rabin Medical Center, Petah Tikva, Tel Aviv University, Tel Aviv, Israel (R.Y.); Alexandra Regional General Hospital, Athens (F.Z.); Institut Jules Bordet, Brussels (A.G.); Queen Mary University of London, London (P.S.), and Edinburgh Cancer Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh (D.A.C.) - both in the United Kingdom; Daiichi Sankyo, Basking Ridge, NJ (D.G., L.Y., Y.W., J. Singh, P.V., G.M.); and the Breast Center, Department of Obstetrics and Gynecology, and Comprehensive Cancer Center Munich, Ludwig Maximilian University Hospital, Munich, Germany (N.H.).
Article Synopsis
- A study was conducted on patients with "HER2-low" metastatic breast cancer, which means they have low levels of HER2 that could potentially be treated, but existing therapies were not effective.
- In the trial, patients were randomly assigned to receive either trastuzumab deruxtecan or standard chemotherapy after having one or two previous treatments; the main goal was to measure how long patients remained free from disease progression.
- Results showed that those treated with trastuzumab deruxtecan had significantly longer progression-free survival (10.1 months vs. 5.4 months) and overall survival (23.9 months vs. 17.5 months) compared to the standard chemotherapy group, despite a high rate of serious adverse
Important Regulatory Roles of Erythrocytes in Platelet Adhesion to the von Willebrand Factor on the Wall under Blood Flow Conditions.
Thromb Haemost
June 2022
Department of Medicine (Cardiology), Research Center for Metabolic Disease, Tokai University School of Medicine and Tokai University Graduate School of Medicine, Isehara, Japan.
The role of erythrocytes in platelet adhesion to von Willebrand factor (VWF) on the vessel wall through their membrane glycoprotein (GP)Ibα under blood flow conditions has not yet been elucidated. Blood specimens containing fluorescent-labeled platelets and native, biochemically fixed, or artificial erythrocytes at various hematocrits were perfused on the surface of VWF immobilized on the wall at a shear rate of 1,500 s. The rates of platelet adhesion were measured under each condition.
View Article and Find Full Text PDFFukushima Nuclear Power Plant accident: Various issues with iodine distribution and medication orders.
Am J Disaster Med
August 2021
National Graduate Institute for Policy Studies, Health and Global Policy Institute, Tokyo, Japan.
Immediately after the Great East Japan Earthquake on March 11, 2011, the public could not receive accurate information concerning about the reality of the accident at the Fukushima Nuclear Power Plant because of communication problems with mobile phone base stations caused by power outages and the inadequate use of communication satellites between local governments. These telecommunications troubles caused not only a delay between the Japanese central government to local governments, but also a failure in conveying the seriousness of the accident to residents. The central government issued evacuation orders, but in some areas, a delay was seen in the time residents took to notice the orders.
View Article and Find Full Text PDFA Lung Sound Analysis in Infants with Risk Factors for Asthma During Acute Respiratory Infection.
Pediatr Allergy Immunol Pulmonol
September 2020
Department of Pediatrics and Tokai University School of Medicine, Isehara, Japan.
The parameters of lung sounds have been suggested as biomarkers of airway changes. Using a commercially available lung sound analyzer, we investigated the characteristics of the lung sounds in infants with acute respiratory infection (ARI). Infants with ARI who were 6 to 18 months of age were included in this study.
View Article and Find Full Text PDFA case of pericecal hernia with a hernial orifice located on the lateral side of the cecum.
Tokai J Exp Clin Med
September 2011
Department of Digestive Surgery, School of Medicine, Tokai University Oiso Hospital, and Tokai University, 21-1 Gakkyou, Oiso, Kanagawa 259-0198 Japan.
The patient was a female in her 70s without previous laparotomy who visited our hospital for right lower abdominal pain. Marked small intestinal gas was noted on plain abdominal X-ray radiography. The patient was diagnosed with ileus and admitted.
View Article and Find Full Text PDFThe role of high-sensitivity C-reactive protein in asymptomatic intra- and extracranial large artery diseases.
Cerebrovasc Dis
January 2009
Department of Neurology, Tokai University School of Medicine and Tokai University Hachiohji Hospital, HIMEDIC Imaging Center at Lake Yamanaka, Kanagawa, Japan.
Background: It remains unclear whether high-sensitivity CRP (hs-CRP) is predictive of atherosclerosis in the intracranial artery. The aim of this study is to assess the role of hs-CRP in asymptomatic intracranial artery occlusive diseases.
Methods: Of the 3,366 apparently healthy subjects who received a brain checkup, 138 with > or =25% intracranial artery stenosis on magnetic resonance angiography, 267 with > or =25% extracranial carotid artery stenosis on B-mode ultrasonography and 435 without intracranial artery or extracranial carotid artery stenosis (age-matched controls) were selected for this study.